Injectable Flea Treatment Received Promising Feedback from EMA

The European Medicines Agency has released a promising review for MSD’s Bravecto. If it receives clearance, it would be the “first and only once-yearly injectable flea and tick medication” for canines. 

MSD stated that it was collaborating with many regulatory agencies to quickly launch the injectable treatment globally. 

The injectable would be offered for use in EU nations by veterinary professionals for administration to canines aged 6 months and over. 

One of the leading bodies of MSD Animal Health, Rick DeLuca, commented, “MSD Animal Health has been committed to bringing innovations to our customers that protect pets longer from flea and tick infestations and the associated health risks.” 

DeLuca went on to add, “With the positive opinion of this injectable formulation of Bravecto, the first and only once-yearly injectable flea and tick medication, pet owners are one step closer to a new, convenient option to help ensure year-round comprehensive protection from fleas and ticks without the need for administering multiple doses of medication.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.